Erratum: "Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation" (Hepatology (2008) vol. 48 (732-740) 10.1002/hep.22422);Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation

Hepatology

Volumn 48, Issue 3, 2008, Pages 732-740

  Kato, Takanobu ^a,b,c   Choi, Youkyung ^d   Elmowalid, Gamal ^a   Sapp, Ronda K ^a   Barth, Heidi ^a   Furusaka, Akihiro ^e,f   Mishiro, Shunji ^b   Wakita, Takaji ^c   Krawczynski, Krzysztof ^d   Liang, T Jake ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b Shinagawa ku   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOKYO METROPOLITAN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN JFH 1; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CHIMPANZEE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSFECTION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCHEMISTRY; IN VIVO STUDY; INOCULATION; MUTATIONAL ANALYSIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; VIREMIA; VIRUS CELL INTERACTION; VIRUS IDENTIFICATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

EID: 51349088324     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22718     Document Type: Erratum

References (47)

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.
2. Feld JJ, Liang TJ. Hepatitis C: Identifying patients with progressive liver injury. HEPATOLOGY 2006;43(Suppl):S194-S206.
3. Shiina M, Rehermann B. Hepatitis C vaccines: Inducing and challenging memory T cells. HEPATOLOGY 2006;43:1395-1398.
4. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005;436:953-960.
5. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. HEPATOLOGY 2002;36(Suppl):S121-S127.
6. Kato T, Furusaka A, Miyamoto M, Date T, Yasui K, Hiramom J, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 2001;64:334-339.
7. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005;102:9294-9299.
8. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.
9. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
10. Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle RE, et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A 2002;99:14416-14421.
11. Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, et al. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol 2007;81:5036-5045.
12. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T. Cell culture and infection system for hepatitis C virus. Nat Protoc 2006;1: 2334-2339.
13. Takeuchi T, Katsume A, Tanaka T, Abe A, Inoue K, Tsukiyama-Kohara K, et al. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 1999;116:636-642.
14. Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A 2007;104:8427-8432.
15. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999;37:1802-1808.
16. Kato T, Matsumura T, Heller T, Saito S, Sapp RK, Murthy K, et al. Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol 2007;81:4405-4411.
17. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15:883-895.
18. Gastaminza P, Kapadia SB, Chisari FV. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 2006;80:11074-11081.
19. Wright TL, Hsu H, Donegan E, Feinstone S, Greenberg H, Read A, et al. Hepatitis C virus not found in fulminant non-A, non-B hepatitis. Ann Intern Med 1991;115:111-112.
20. Liang TJ, Jeffers L, Reddy RK, Silva MO, Cheinquer H, Findor A, et al. Fulminant or subfulminant non-A, non-B viral hepatitis: The role of hepatitis C and E viruses. Gastroenterology 1993;104:556-562.
21. Yoshiba M, Dehara K, Inoue K, Okamoto H, Mayumi M. Contribution of hepatitis C virus to non-A, non-B fulminant hepatitis in Japan. HEPATOLOGY 1994;19:829-835.
22. Villamil FG, Hu KQ, Yu CH, Lee CH, Rojter SE, Podesta LG, et al. Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure. HEPATOLOGY 1995;22:1379-1386.
23. Vento S, Cainelli F, Mirandola F, Cosco L, Di Perri G, Solbiati M, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancer 1996;347:92-93.
24. Farci P, Alter HJ, Shimoda A, Govindarajan S, Cheung LC, Melpolder JC, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996;335:631-634.
25. Fukai K, Yokosuka O, Fujiwara K, Tagawa M, Imazeki F, Saisho H, et al. Etiologic considerations of fulminant non-A, non-B viral hepatitis in Japan: Analyses by nucleic acid amplification method. J Infect Dis 1998;178: 325-333.
26. Farci P, Munoz SJ, Shimoda A, Govindarajan S, Wong DC, Coiana A, et al. Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee. J Infect Dis 1999;179:1007-1011.
27. Sakai A, Takikawa S, Thimme R, Meunier JC, Spangenberg HC, Govindarajan S, et al. In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells. J Virol 2007;81:7208-7219.
28. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997;277:570-574.
29. Hong Z, Beaudet-Miller M, Lanford RE, Guerra B, Wright-Minogue J, Skelton A, et al. Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees. Virology 1999;256:36-44.
30. Beard MR, Abell G, Honda M, Carroll A, Gartland M, Clarke B, et al. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. HEPATOLOGY 1999;30:316-324.
31. Thomson M, Nascimbeni M, Gonzales S, Murthy KK, Rehermann B, Liang TJ. Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus. Gastroenterology 2001;121:1226-1233.
32. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002;76:6586-6595.
33. Kojima M, Osuga T, Tsuda F, Tanaka T, Okamoto H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees. Virology 1994; 204:665-672.
34. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339-344.
35. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15:883-895.
36. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004;200:1593-1604.
37. Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouille Y, Dubuisson J, et al. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol 2007;88:2495-2503.
38. Kaul A, Woerz I, Meuleman P, Leroux-Roels G, Bartenschlager R. Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol 2007;81:13168-13179.
39. Russell RS, Meunier JC, Takikawa S, Faulk K, Engle RE, Bukh J, et al. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A 2008;105:4370-4375.
40. Lorenz IC, Marcotrigiano J, Dentzer TG, Rice CM. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 2006;442: 831-835.
41. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
42. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003;125:1808-1817.
43. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007;81:8374-8383.
44. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006;103:7408-7413.
45. Yi M, Ma Y, Yates J, Lemon SM. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 2007;81:629-638.
46. Yamaga AK, Ou JH. Membrane topology of the hepatitis C virus NS2 protein. J Biol Chem 2002;277:33228-33234.
47. Murray CL, Jones CT, Tassello J, Rice CM. Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus. J Virol 2007;81:10220-10231.